Eli Lilly and Company (NYSE:LLY) Shares Acquired by Zhang Financial LLC

Zhang Financial LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 2.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,672 shares of the company’s stock after buying an additional 34 shares during the period. Zhang Financial LLC’s holdings in Eli Lilly and Company were worth $975,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $3,416,206,000. International Assets Investment Management LLC lifted its position in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its position in Eli Lilly and Company by 102,752.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares during the last quarter. Morgan Stanley lifted its position in Eli Lilly and Company by 44.1% in the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares during the last quarter. Finally, Imprint Wealth LLC lifted its position in Eli Lilly and Company by 53,716.8% in the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after purchasing an additional 1,747,946 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, Citigroup upped their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Trading Down 2.6 %

Shares of NYSE LLY opened at $726.31 on Friday. Eli Lilly and Company has a 12 month low of $369.76 and a 12 month high of $800.78. The company has a market cap of $690.11 billion, a price-to-earnings ratio of 125.23, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The business has a fifty day simple moving average of $763.96 and a 200-day simple moving average of $659.59.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.